Emmanuel Quinaux

6.9k total citations · 2 hit papers
37 papers, 4.9k citations indexed

About

Emmanuel Quinaux is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Emmanuel Quinaux has authored 37 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 14 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Emmanuel Quinaux's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (13 papers) and Breast Cancer Treatment Studies (10 papers). Emmanuel Quinaux is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (13 papers) and Breast Cancer Treatment Studies (10 papers). Emmanuel Quinaux collaborates with scholars based in Belgium, France and United States. Emmanuel Quinaux's co-authors include Marc Buyse, Thierry André, Aimery de Gramont, Gérard Lledo, Emmanuel Achille, Christophe Louvet, Christophe Tournigand, D. Méry-Mignard, G. Ganem and Bruno Landi and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.

In The Last Decade

Emmanuel Quinaux

37 papers receiving 4.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

2003 2.3k citations Christophe Tournigand, Thierry André et al. Journal of Clinical Oncology profile →
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

2013 1.2k citations Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emmanuel Quinaux Belgium	18	4.2k	1.3k	1.1k	768	656	37	4.9k
Erika Hitre Hungary	21	4.4k 1.0×	1.5k 1.1×	811 0.7×	985 1.3×	809 1.2×	60	5.5k
Bruce J. Giantonio United States	31	3.4k 0.8×	1.6k 1.2×	959 0.9×	748 1.0×	1.3k 1.9×	124	5.0k
Claus‐Henning Köhne Germany	27	3.1k 0.7×	1.2k 0.9×	1.1k 1.0×	613 0.8×	763 1.2×	75	4.3k
Mark Kozloff United States	36	3.2k 0.8×	1.7k 1.3×	454 0.4×	702 0.9×	1.3k 2.0×	125	4.7k
Allen Lee Cohn United States	38	4.7k 1.1×	2.4k 1.8×	1.2k 1.1×	1.3k 1.6×	1.5k 2.4×	159	6.9k
Dominik Paul Modest Germany	36	3.5k 0.8×	1.6k 1.2×	900 0.8×	812 1.1×	620 0.9×	206	4.4k
Guy van Hazel Australia	26	3.7k 0.9×	1.8k 1.4×	1.1k 1.0×	894 1.2×	446 0.7×	66	5.2k
Dirk Arnold Germany	17	2.9k 0.7×	921 0.7×	614 0.6×	1.1k 1.4×	859 1.3×	108	4.1k
M. Mueser France	10	3.8k 0.9×	1.9k 1.5×	779 0.7×	464 0.6×	795 1.2×	18	4.5k
Rafael G. Amado United States	21	5.0k 1.2×	2.3k 1.8×	1.4k 1.2×	1.1k 1.4×	1.2k 1.8×	57	6.7k

Countries citing papers authored by Emmanuel Quinaux

Since Specialization

Citations

This map shows the geographic impact of Emmanuel Quinaux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuel Quinaux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuel Quinaux more than expected).

Fields of papers citing papers by Emmanuel Quinaux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuel Quinaux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuel Quinaux. The network helps show where Emmanuel Quinaux may publish in the future.

Co-authorship network of co-authors of Emmanuel Quinaux

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuel Quinaux. A scholar is included among the top collaborators of Emmanuel Quinaux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuel Quinaux. Emmanuel Quinaux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Quinaux, Emmanuel, et al.. (2023). Minimization in randomized clinical trials. Statistics in Medicine. 42(28). 5285–5311. 10 indexed citations

Saad, Everardo D., Pierre Squifflet, Tomasz Burzykowski, et al.. (2019). Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. The Lancet Oncology. 20(3). 361–370. 49 indexed citations

Press, Michael F., José A. Seoane, Christina Curtis, et al.. (2018). Assessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncology. 5(3). 366–366. 25 indexed citations

Press, Michael F., Guido Sauter, Marc Buyse, et al.. (2016). HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials.. Journal of Clinical Oncology. 34(15_suppl). 515–515. 1 indexed citations

Delbaldo, Catherine, Marc Ychou, Ayman Zawadi, et al.. (2015). Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial. Annals of Oncology. 26(6). 1208–1215. 9 indexed citations

Sonnenblick, Amir, Prudence A. Francis, Hatem A. Azim, et al.. (2015). Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer. 51(12). 1481–1489. 28 indexed citations

Soveri, Leena‐Maija, Aimery de Gramont, Tuija Poussa, et al.. (2014). Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?. European Journal of Cancer. 50(17). 2966–2974. 24 indexed citations

Loi, Sherene, Nicolas Sirtaine, Fanny Piette, et al.. (2013). Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology. 31(7). 860–867. 1213 indexed citations breakdown →

Delbaldo, Catherine, D. Serin, M Mousseau, et al.. (2013). A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000). European Journal of Cancer. 50(1). 23–30. 7 indexed citations

10.

Christiansen, Jason, Nashwa Barakat, Derek Murphy, et al.. (2012). Abstract PD02-01: Her2 expression measured by AQUA analysis on BCIRG-005 and BCIRG-006 predicts the benefit of Herceptin therapy. Cancer Research. 72(24_Supplement). PD02–1. 1 indexed citations

11.

Fernandez‐Cuesta, Lynnette, Catherine Oakman, Priscila Falagan-Lotsch, et al.. (2012). Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Research. 14(3). R70–R70. 46 indexed citations

12.

Loi, Sherene, Rodrigo Salgado, Fanny Piette, et al.. (2011). Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT).. Journal of Clinical Oncology. 29(15_suppl). 556–556. 5 indexed citations

13.

Baumgaertner, Isabelle, Emmanuel Quinaux, Ahmed Khalil, et al.. (2010). Comparison of the Levogyre and Dextro-Levogyre Forms of Leucovorin in a Phase III Trial of Bimonthly LV5FU2 Versus Monthly 5-Fluorouracil and High-Dose Leucovorin for Patients With Stage II and III Colon Cancer (GERCOR C96.1). Clinical Colorectal Cancer. 9(2). E5–E10. 3 indexed citations

14.

Leo, Angelo Di, Prudence A. Francis, John Crown, et al.. (2009). Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial.. Cancer Research. 69(24_Supplement). 601–601. 6 indexed citations

15.

Gramont, Aimery de, Marc Buyse, José Cortiñas Abrahantes, et al.. (2007). Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology. 25(22). 3224–3229. 103 indexed citations

16.

Quinaux, Emmanuel, et al.. (2006). Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer. Clinical Trials. 3(5). 486–492. 43 indexed citations

17.

André, Thierry, Emmanuel Quinaux, Christophe Louvet, et al.. (2005). Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients. Journal of Clinical Oncology. 23(16_suppl). 3522–3522. 13 indexed citations

18.

Tournigand, Christophe, Thierry André, Emmanuel Achille, et al.. (2003). FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. Journal of Clinical Oncology. 22(2). 229–237. 2290 indexed citations breakdown →

19.

Nevens, Frederik, Tania Roskams, Hans Van Vlierberghe, et al.. (2003). A Pilot Study of Therapeutic Vaccination With Envelope Protein E1 in 35 Patients With Chronic Hepatitis C. Hepatology. 38(5). 1289–1296. 102 indexed citations

20.

Llorca, F. Penault, Xavier Sastre, Maryse Fiche, et al.. (1999). Pathological response to neoadjuvant chemotherapy Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification. Breast Cancer Research and Treatment. 57(1). 67. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact